AAIC 2026: Early Detection and Preclinical AD

Early Detection and Preclinical Alzheimer's Disease at AAIC 2026

AAIC 2026 showcased significant advances in early detection of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), focusing on identifying pathological changes before clinical symptoms emerge. The shift toward preclinical intervention represents a fundamental change in AD research and clinical practice.

Conceptual Framework

Preclinical AD Staging

The preclinical AD framework continues to evolve[@sperling2011]:

• Stage 1: Amyloid positivity without neurodegeneration or cognitive impairment
• Stage 2: Amyloid + neurodegeneration (AD signature region atrophy, FDG hypometabolism, or [tau](/proteins/tau) PET positivity)
• Stage 3: Amyloid + neurodegeneration + subtle cognitive changes

Biomarker Staging Models

New integrated biomarker approaches:

• AT(N) classification: Amyloid (A), Tau (T), Neurodegeneration (N)
• Blood-based biomarkers: Adding AT(Blood) to the framework
• Dynamic biomarkers: Rate of change as predictive markers

Blood-Based Biomarker Screening

Population-Level Screening

Advances in blood biomarker implementation[@schindler2024]:

• Primary care integration: Feasibility studies in community settings
• At-risk populations: Screening in individuals with family history, cardiovascular disease, or diabetes
• Cost-effectiveness: Modeling for population screening programs

Implementation Challenges

Practical considerations discussed at AAIC 2026:

Early Detection and Preclinical Alzheimer's Disease at AAIC 2026

AAIC 2026 showcased significant advances in early detection of [Alzheimer's disease](/diseases/alzheimers-disease) (AD), focusing on identifying pathological changes before clinical symptoms emerge. The shift toward preclinical intervention represents a fundamental change in AD research and clinical practice.

Conceptual Framework

Preclinical AD Staging

The preclinical AD framework continues to evolve[@sperling2011]:

• Stage 1: Amyloid positivity without neurodegeneration or cognitive impairment
• Stage 2: Amyloid + neurodegeneration (AD signature region atrophy, FDG hypometabolism, or [tau](/proteins/tau) PET positivity)
• Stage 3: Amyloid + neurodegeneration + subtle cognitive changes

Biomarker Staging Models

New integrated biomarker approaches:

• AT(N) classification: Amyloid (A), Tau (T), Neurodegeneration (N)
• Blood-based biomarkers: Adding AT(Blood) to the framework
• Dynamic biomarkers: Rate of change as predictive markers

Blood-Based Biomarker Screening

Population-Level Screening

Advances in blood biomarker implementation[@schindler2024]:

• Primary care integration: Feasibility studies in community settings
• At-risk populations: Screening in individuals with family history, cardiovascular disease, or diabetes
• Cost-effectiveness: Modeling for population screening programs

Implementation Challenges

Practical considerations discussed at AAIC 2026:

• Assay standardization across laboratories
• Cut-point determination for clinical use
• Disclosure protocols for positive results

Sensitive Detection Methods

Ultra-Sensitive Assays

Single-molecule array (Simoa) and other ultrasensitive platforms:

• Detecting [amyloid-beta](/proteins/amyloid-beta) at concentrations 100x lower than standard assays
• [p-Tau217](/biomarkers/p-tau-217) elevation in cognitively normal individuals with amyloid positivity
• [GFAP](/entities/gfap) as early marker of astrocyte reactivity

Multimodal Screening

Combining blood biomarkers with other assessments:

• Blood + genetic testing ([APOE](/proteins/apoe) genotyping)
• Blood + digital biomarkers
• Blood + brief cognitive assessments

Cognitive Precursors

Subtle Cognitive Changes

Detecting earliest cognitive manifestations[@bondi2022]:

• Preclinical Cognitive Impairment: Deficits detectable with sensitive neuropsychological tests
• Objective Subtle Cognitive Difficulties (Obj-SCD): Validated assessment approaches
• Cognitive reserve effects: Understanding resilience to pathology

Digital Biomarkers

Technology-enabled cognitive assessment:

• Smartphone-based cognitive testing
• Wearable sensor data for behavioral changes
• Voice analysis for language alterations

Neuroimaging in Early Detection

Amyloid PET Screening

Utilizing PET for early detection:

• Centiloid scale standardization
• Low-dose protocols for screening
• Visual read standardization

Tau PET Sensitivity

Early tau detection advances:

• p-Tau231 as preclinical marker
• [Entorhinal cortex](/brain-regions/entorhinal-cortex) tau as earliest detectable pathology
• Tau spreading patterns in preclinical stages

MRI Markers

Structural MRI in preclinical AD:

• Hippocampal atrophy rates
• Default mode network connectivity changes
• White matter microstructural changes

Risk Prediction Models

Genetic Risk

Polygenic risk scores for AD[@karch2022]:

• Combined APOE and non-APOE genetic variants
• Risk stratification for prevention trials
• Interaction with lifestyle factors

Composite Risk Scores

Integrating multiple risk factors:

• Demographic (age, sex, education)
• Genetic (APOE, polygenic risk)
• Biomarker (fluid, imaging)
• Lifestyle (physical activity, diet, cardiovascular)

Prevention Trial Updates

Enrollment Strategies

Recruitment for preclinical AD trials:

• Blood biomarker-based screening efficiency
• Family history enrichment strategies
• Diverse population recruitment

Primary Prevention Trials

Trials targeting amyloid removal in preclinical populations:

• Anti-amyloid antibodies in cognitively normal amyloid-positive individuals
• Outcome measures for prevention trials
• Ethical considerations in presymptomatic intervention

Clinical Implications

Diagnostic Criteria Updates

Recent revisions to AD diagnostic criteria:

• NIA-AA criteria for preclinical AD
• IWG criteria for presymptomatic AD
• Implementation in clinical practice

Clinical Practice Guidelines

Recommendations for early detection:

• When to offer biomarker testing
• Counseling for individuals with preclinical AD
• Monitoring recommendations

Future Directions

Key areas for future research:

Overview

This page provides information about AAIC 2026: Early Detection and Preclinical AD.

See Also

• [NeuroWiki Home](/home)

References